

Megan Othus

1100 Fairview Avenue North
M3-C102
PO Box 19024
Seattle, WA 98109-1024

Cell: (503) 449-8943
Office: (206) 667-5749
mothus@fhcrc.org

EDUCATION

Harvard University, Cambridge, MA

Ph.D., Biostatistics, June 2009

Dissertation: “Survival Analysis with Complex Censoring Mechanisms with Application in Population-based Studies and Clinical Trials”

Advisor: Yi Li

A.M., Biostatistics, June 2006

Reed College, Portland, OR

B.A., Mathematics, May 2004

Thesis: “An Analysis of the Relative Risk of Cancer Mortality Among Atomic Bomb Survivors”

Advisor: Albyn Jones

PROFESSIONAL POSITIONS

Associate Member, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 2014–present

Affiliate Associate Professor, Department of Biostatistics, University of Washington, Seattle, WA 2015–present

Affiliate Assistant Professor, Department of Biostatistics, University of Washington, Seattle, WA 2011–2015

Assistant Member, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 2009–2014

HONORS AND AWARDS

Dr. Charles A. Coltman, Jr. Fellowship 2011

Hope Foundation

Statistics in Epidemiology Student Travel Award 2009

American Statistical Association

Byar Young Investigator Travel Award 2008

American Statistical Association

Health Policy Statistics Student Paper Award 2008

American Statistical Association

Distinguished Student Paper Award 2008

International Biometric Society Eastern North American Region

Student Paper Award 2008

International Chinese Statistics Association

Contributed Talk Award 2008

Frontiers in Applied and Computational Mathematics

Certificate of Distinction in Teaching	2008
<i>Derek Bok Center for Teaching and Learning at Harvard University</i>	
Award for Best Teaching Assistant	2007
<i>Harvard School of Public Health</i>	
Certificate of Distinction in Teaching	2006–2007
<i>Harvard University Department of Biostatistics</i>	
Mu Sigma Rho	2007
Phi Beta Kappa	2004

RESEARCH
INTERESTS

Clinical trial design and analysis, survival analysis, cure modeling

PROFESSIONAL
ACTIVITY

Statistical Reviewer, Clinical Cancer Research	2014 – present
Member, NCI Leukemia Steering Committee	2013 – present
Statistical Advisor, BioMed Central	2013 – present
Member, HVTN Safety Monitoring Board	2012 – present
Secretary, WNAR	2012 – present
Co-organizer, FHCRC Biostatistics Seminar Series	2012 – 2013
Co-organizer, SWOG Young Investigators Course	2011 – present

PROFESSIONAL
MEMBERSHIPS

American Statistical Association, Western North American Region of the International Biometric Society

REFEREE

BMC Anesthesiology, BMC Cancer, Biomedical Journal, Biometrics, Biostatistics, British Journal of Cancer, Cancer, Clinical Cancer Research, Clinical Trials, Communications in Statistics - Simulation and Computation, Computational Statistics and Data Analysis, European Series in Applied and Industrial Mathematics: Probability and Statistics, Haematologica, International Journal of Biostatistics, JAMA Oncology, Journal of the American Statistical Association, Journal of Applied Statistics, Journal of Multivariate Analysis, Journal of the Royal Statistical Society Series (JRSS) A, JRSSB, JRSSC, Lifetime Data Analysis, Pharmaceutical Statistics, PLOS ONE, Statistics in Biosciences, Statistics in Medicine

INVITED TALKS

Department of Mathematics, Whitman College, Walla Walla, WA, September 2013
 Department of Mathematics, Reed College, Portland, OR, November 2012
 Department of Biostatistics, University of Washington, Seattle, WA, March 2011
 Department of Mathematics, Reed College, Portland, OR, December 2010
 Department of Mathematical and Statistical Sciences, University of Colorado, Denver, CO, February, 2009

Department of Biostatistics and Informatics, University of Colorado, Denver, CO, February 2009

Department of Biostatistics, University of Washington, Seattle, WA, February 2009

Program in Biostatistics and Biomathematics, Fred Hutchinson Cancer Research Center, Seattle, WA, February 2009

Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, February 2009

Center for Statistical Sciences, Department of Community Health, Brown University, Providence, RI, January 2009

Department of Biostatistics, UCLA, Los Angeles, CA, January 2009

Clinical Trial Fellows Seminar Series, Beth Israel Deaconess Medical Center, Boston, MA, April 2008

Clinical Trial Fellows Seminar Series, Beth Israel Deaconess Medical Center, Boston, MA, March 2008

Cancer Working Group Seminar Series, Harvard, Biostatistics Department, Boston, MA, February 2008

CONFERENCE
PRESENTATIONS

WNAR, Honolulu, HI, June 2014

American Society of Hematology Annual Meeting, Atlanta, GA, December 2012

Society for the Advancement of Chicanos and Native Americans in Science National Conference, Seattle, WA, October 2012

ENAR, Miami, FL, March 2011

International Conference on Statistics and Society, Beijing, China, July 2010

International Conference on Statistical Analysis of Complex Data, Kunming, China, July 2010

Joint Statistical Meetings, Washington DC, August 2009

New England Statistics Symposium, Storrs CT, April 2009

Joint Statistical Meetings, Denver, CO, August 2008

International Chinese Statistical Association Applied Statistics Symposium, Piscataway, NJ, June 2008

Frontiers of Applied and Computational Mathematics, Newark, NJ, May 2008

ENAR, Arlington, VA, March 2008

BOOK
CHAPTERS

Published

1. **Othus M**, Crowley J, Barlogie B. Cure-rate Survival Models in Clinical Trials. In: Crowley J, Hoering A (eds): Handbook of Statistics in Clinical Oncology (Edition 3). 2012. CRC Press.

PAPERS

Published or In Press

1. J. Vaughn, **M. Othus**, M. Powell, K. Gardner, D. Rizzuto, P. Hendrie, P. Becker, P. Pottinger, E. Estey, and R. Walter, “Comparative analysis of resource utilization and safety of outpatient management following intensive AML induction/salvage chemotherapy,” *JAMA Oncology*, in press.
2. R. Walter, **M. Othus**, B. Lowenberg, G. Ossenkoppele, S. Petersdorf, T. Pabst, M.-C. Vekemans, F. Appelbaum, H. Erba, and E. Estey, “Definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: Analysis of 1,892 patients from HOVON/SAKK and SWOG,” *Haematologica*, in press.
3. M. Bar, **M. Othus**, H. Park, V. Sandu, X. Chen, B. Wood, and E. Estey, “Elevated lymphocyte count at time of acute myeloid leukemia diagnosis is associated with shorter remission,” *Leukemia & Lymphoma*, in press. PMID: 25726954.
4. D. Araki, **M. Othus**, R. Walter, V. Sandhu, B. Sandmaier, P. Becker, F. Appelbaum, and E. Estey, “Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse CR rate and survival in acute myeloid leukemia,” *Haematologica*, in press.
5. R. Walter, **M. Othus**, E. Paietta, J. Racevskis, H. Fernandez, J.-W. Lee, Z. Sun, M. Tallman, J. Patel, M. Gonen, O. Abdel-Wahab, R. Levine, and E. Estey, “Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia,” *Leukemia*, in press. PMID: 25772026.
6. S. Buckley, **M. Othus**, E. Estey, and R. Walter, “The treatment related mortality (TRM) score is associated with non-fatal adverse events following intensive AML induction chemotherapy,” *Blood Cancer Journal*, in press. PMID: 25635529.
7. S. Lee, J. Moon, B. Redman, T. Chidiac, L. Flaherty, Y. Zha, **M. Othus**, A. Ribas, V. Sondak, T. Gajewski, and K. Margolin, “A phase II study of RO4929097 gamma-secretase inhibitor in metastatic melanoma: SWOG 0933,” *Cancer*(3), pages 432–440, 2015. PMCID: PMC4304973.
8. B. Medeiros, **M. Othus**, M. Fang, F. Appelbaum, and H. Erba, “Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia,” *Haematologica*(3), pages 331–335, 2015. PMCID: PMC4349271.
9. F. Ostronoff, **M. Othus**, M. Lazenby, E. Estey, F. Appelbaum, A. Evans, J. Godwin, A. Gilkes, K. Kopecky, A. Burnett, A. List, M. Fang, V. Oehler, S. Petersdorf, E. Pogossova-Agadjanyan, J. Radich, C. Willman, S. Meshinchi, and D. Stirewalt, “Prognostic significance of NPM1 mutations in the absence of FLT3-ITD in older patients with AML: A SWOG and MRC/NCRI report,” *Journal of Clinical Oncology*(10), pages 1157–1164, 2015. PMCID: PMC4372852.
10. P. Becker, B. Medeiros, A. Stein, **M. Othus**, F. Appelbaum, S. Forman, B. Scott, P. Hendrie, K. Gardner, J. Pagel, R. Walter, C. Parks, B. Wood, J. Abkowitz, and E. Estey, “G-CSF riming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm,” *American Journal of Hematology*, 90(4), pages 295–300, 2015. PMID: 25545153.

11. M. Bar, W. Tong, **M. Othus**, K. Loeb, and E. Estey, "Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation," *Biology of Blood and Marrow Transplantation*, 21(3), pages 546–551, 2015. PMID: 25545726.
12. **M. Othus**, F. Appelbaum, P. Petersdorf, K. Kopecky, M. Slovak, T. Nevill, J. Brandwein, R. Larson, P. Stiff, R. Walter, M. Tallman, and H. Erba, "The fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy biology of blood and marrow transplantation," *Biology of Blood and Marrow Transplantation*, 21(3), pages 559–564, 2015. PMCID: PMC4386840.
13. R. Walter, **M. Othus**, A. Burnett, B. Lowenberg, H. Kantarjian, G. Ossenkoppele, R. Hills, F. Ravandi, T. Pabst, A. Evans, S. Pierce, M. Vekemans, F. Appelbaum, and E. Estey, "Resistance prediction in AML: Analysis of 4,601 patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center," *Leukemia*, 29(2), pages 312–320, 2015. PMCID: PMC4318722.
14. R. Walter, G. Laszlo, J. Lionberger, J. Pollard, K. Harrington, C. Gudgeon, **M. Othus**, S. Rafii, S. Meshinchi, F. Appelbaum, *et al.*, "Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia," *Leukemia*, 28(10), pages 1969–1977, 2014. PMCID: PMC4167978.
15. L. E. Flaherty, **M. Othus**, M. B. Atkins, R. J. Tuthill, J. A. Thompson, J. T. Vetto, F. G. Haluska, A. S. Pappo, J. A. Sosman, B. G. Redman, *et al.*, "Southwest Oncology Group S0008: A phase III trial of high-dose Interferon alfa-2b versus Cisplatin, Vinblastine, and Dacarbazine, plus Interleukin-2 and Interferon in patients with high-risk melanomaAn Intergroup study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group," *Journal of Clinical Oncology*, 32(33), pages 3771–3778, 2014. PMCID: PMC4226807.
16. R. Hills, S. Castaigne, F. Applebaum, J. Delaunay, S. Petersdorf, **M. Othus**, E. Estey, H. Dombret, S. Chevret, N. Ifrah, J.-Y. Cahn, C. Recher, L. Chilton, A. Moorman, and A. Burnett, "Addition of Gemtuzumab Ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials," *Lancet Oncology*, 15(9), pages 986–996, 2014. PMCID: PMC4137593.
17. A. Advani, S. McDonough, E. Copelan, C. Willman, D. Mulford, A. List, M. Sekeres, **M. Othus**, H. Erba, and F. Appelbaum, "SWOG0919: A Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia," *British Journal of Haematology*, 167(2), pages 233–237, 2014. PMCID: PMC4188732.
18. F. Ostronoff, **M. Othus**, R. Gerbing, M. Loken, S. Raimondi, B. Hirsch, B. Lange, S. Petersdorf, J. Radich, F. Appelbaum, A. Gamis, T. Alonzo, and S. Meshinchi, "NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: A COG and SWOG report," *Blood*, 124(15), pages 2400–2407, 2014. PMCID: PMC419275.

19. W. Carson, J. Unger, J. Sosman, L. Flaherty, R. Tuthill, M. Porter, P. Terasaki, J. Thompson, R. Kempf, **A. M. Othus**, Ribas, and V. Sondak, “Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: Long-term outcome and impact of HLA class I antigen expression on overall survival,” *Cancer Immunology Research*, 2(10), pages 981–987, 2014. PMID: PMC4185232.
20. S. A. Buckley, **M. Othus**, V. Vainstein, J. L. Abkowitz, E. H. Estey, and R. B. Walter, “Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes,” *American Journal of Hematology*, 89(4), pages 423–428, 2014. PMID: PMC4391649.
21. A. S. Advani, S. McDonough, S. Coutre, B. Wood, J. Radich, M. Mims, M. O’Donnell, S. Elkins, M. Becker, **M. Othus**, and F. R. Appelbaum, “SWOG S0910: A phase 2 trial of clofarabine/cytarabine/epirubicin for relapsed/refractory acute lymphocytic leukaemia,” *British Journal of Haematology*, 165(4), pages 504–509, 2014. PMID: PMC4188732.
22. S. E. Coutre, **M. Othus**, B. Powell, C. L. Willman, W. Stock, E. Paietta, D. Levitan, M. Wetzler, E. C. Attar, J. K. Altman, S. D. Gore, T. Maher, K. J. Kopecky, M. S. Tallman, R. A. Larson, and F. R. Appelbaum, “Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy,” *British Journal of Haematology*, 165(4), pages 497–503, 2014. PMID: PMC4064464.
23. B. C. Medeiros, **M. Othus**, E. H. Estey, M. Fang, and F. R. Appelbaum, “Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia,” *British Journal of Haematology*, 164(2), pages 245–250, 2014. PMID: PMC4117470.
24. H. P. Erba, **M. Othus**, R. B. Walter, M. H. Kirschbaum, M. S. Tallman, R. A. Larson, M. L. Slovak, K. J. Kopecky, H. M. Gundacker, and F. R. Appelbaum, “Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432,” *Leukemia Research*, 38(3), pages 329–333, 2013. PMID: PMC4247790.
25. **M. Othus**, H. Kantarjian, S. Petersdorf, F. Ravandi, J. Godwin, J. Cortes, S. Pierce, H. Erba, S. Faderl, F. Appelbaum, and E. Estey, “Declining rates of treatment-related mortality in patients with newly diagnosed AML given “intense” induction regimens: A report from SWOG and MD Anderson,” *Leukemia*, 28(2), pages 289–292, 2013. PMID: 23760400.
26. S. Nand, **M. Othus**, J. E. Godwin, C. L. Willman, T. H. Norwood, D. S. Howard, S. E. Coutre, H. P. Erba, and F. R. Appelbaum, “A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia,” *Blood*, 122(20), pages 3432–3439, 2013. PMID: PMC3829116.
27. W. G. Woods, A. R. Franklin, T. A. Alonzo, R. B. Gerbing, K. A. Donohue, **M. Othus**, J. Horan, F. R. Appelbaum, E. H. Estey, C. D. Bloomfield, and R. Larson, “Outcome of adolescents and young adults with acute myeloid leukemia treated

- on COG trials compared to CALGB and SWOG trials,” *Cancer*, 119(23), pages 4170–4179, 2013. PMID: 23833872.
28. F. Ostronoff, **M. Othus**, H. M. Kantarjian, S. Meshinchi, F. Ravandi, P. C. Hendrie, S. Faderl, P. S. Becker, J. E. Cortes, J. M. Pagel, S. H. Petersdorf, J. E. Godwin, C. L. Willman, S. A. Pierce, A. F. List, R. K. Sandhu, R. B. Walter, D. L. Stirewalt, F. R. Appelbaum, and E. H. Estey, “A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia,” *British Journal of Haematology*, 163(1), pages 130–132, 2013. PMID: 24128010.
 29. T. L. Chen, E. H. Estey, **M. Othus**, K. M. Gardner, L. J. Markle, and R. B. Walter, “Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: A phase 1/2 study,” *Leukemia & Lymphoma*, 54(11), pages 2534–2536, 2013. PMID: 23863328.
 30. M. Roshal, S. Chien, **M. Othus**, B. Wood, M. Fang, F. Appelbaum, E. Estey, T. Papayannopoulou, and P. Becker, “The proportion of CD34+CD38^{low} or neg myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia,” *Leukemia*, 27(3), pages 728–731, 2013. PMID: 23705906.
 31. R. B. Walter, **M. Othus**, A. K. Burnett, B. Löwenberg, H. M. Kantarjian, G. J. Ossenkoppele, R. K. Hills, K. G. van Montfort, F. Ravandi, A. Evans, S. R. Pierce, F. R. Appelbaum, and E. H. Estey, “Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: Analysis of 5848 newly diagnosed patients,” *Blood*, 121(13), pages 2424–2431, 2013. PMID: 23612855.
 32. A. Lin, **M. Othus**, A. McQuary, M. Chi, and E. Estey, “Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemia,” *Leukemia & Lymphoma*, 54(3), pages 541–546, 2013. PMID: 24451200.
 33. R. C. Shelton, A. C. Snavely, M. De Jesus, **M. Othus**, and J. D. Allen, “HPV vaccine decision-making and acceptance: Does religion play a role?,” *Journal of Religion and Health*, 52(4), pages 1120–1130, 2013. PMID: 22076049.
 34. F. Ostronoff, **M. Othus**, P. Ho, M. Kutny, D. Geraghty, S. Petersdorf, J. Godwin, C. Willman, J. Radich, F. Appelbaum, D. Stirewalt, and S. Meshinchi, “Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: A SWOG report,” *Leukemia*, 27(1), pages 238–241, 2012. PMID: 22722750.
 35. J. E. Karp, E. Garrett-Mayer, E. H. Estey, M. A. Rudek, B. D. Smith, J. M. Greer, D. M. Drye, K. Mackey, K. S. Dorcy, S. D. Gore, M. Levis, M. McDevitt, H. Carraway, K. Pratz, D. Gladston, M. Showel, **M. Othus**, L. A. Doyle, J. J. Wright, and J. M. Pagel, “Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone

- for adults with newly diagnosed, poor-risk acute myelogenous leukemia,” *Haematologica*, 97(11), pages 1736–1742, 2012. PMID: PMC3487449.
36. S. Bhatia, J. Moon, K. A. Margolin, J. S. Weber, C. D. Lao, **M. Othus**, A. M. Aparicio, A. Ribas, and V. K. Sondak, “Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512,” *PloS one*, 7(11), pages e48787, 2012. PMID: PMC3511501.
 37. **M. Othus**, Y. Li, and R. Tiwari, “Change-point cure models with application to estimating the change-point effect of age of diagnosis among prostate cancer patients,” *Journal of Applied Statistics*, 39(4), pages 901–911, 2012. PMID: PMC3337711.
 38. R. B. Walter, **M. Othus**, and E. H. Estey, “Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: A novel paradigm for treatment assignment (response to letter by F. Ferrara),” *Journal of Clinical Oncology*, 30(4), pages 463–464, 2012. PMID: 22184399.
 39. B. C. Medeiros, **M. Othus**, M. Fang, F. R. Appelbaum, and E. H. Estey, “Impact of residual normal metaphases in core binding factor acute myeloid leukemia,” *Cancer*, 118(9), pages 2420–2423, 2012. PMID: PMC3490403.
 40. B. C. Medeiros, **M. Othus**, E. H. Estey, M. Fang, and F. R. Appelbaum, “Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia,” *Haematologica*, 97(9), pages 1401–1404, 2012. PMID: PMC3436242.
 41. **M. Othus**, B. Barlogie, M. L. LeBlanc, and J. J. Crowley, “Cure models as a useful statistical tool for analyzing survival,” *Clinical Cancer Research*, 18(14), pages 3731–3736, 2012. PMID: PMC3744099.
 42. K. A. Margolin, J. Moon, L. E. Flaherty, C. D. Lao, W. L. Akerley, **M. Othus**, J. A. Sosman, J. M. Kirkwood, and V. K. Sondak, “Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438),” *Clinical Cancer Research*, 18(4), pages 1129–1137, 2012. PMID: PMC3481165.
 43. R. B. Walter, **M. Othus**, G. Borthakur, F. Ravandi, J. E. Cortes, S. A. Pierce, F. R. Appelbaum, H. A. Kantarjian, and E. H. Estey, “Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: A novel paradigm for treatment assignment,” *Journal of Clinical Oncology*, 29(33), pages 4417–4424, 2011. PMID: PMC3221524.
 44. M. Fang, B. Storer, E. Estey, **M. Othus**, L. Zhang, B. M. Sandmaier, and F. R. Appelbaum, “Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation,” *Blood*, 118(6), pages 1490–1494, 2011. PMID: PMC3156042.
 45. B. M. Alexander, **M. Othus**, H. B. Caglar, and A. M. Allen, “Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy,” *International Journal of Radiation Oncology* Biology* Physics*, 79(5), pages 1381–1387, 2011. PMID: 20605346.

46. B. Xie, **M. Othus**, B. C. Medeiros, M. Fang, F. R. Appelbaum, and E. H. Estey, "Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype," *Haematologica*, 96(4), pages 631–632, 2011. PMID: PMC3069244.
47. B. Medeiros, **M. Othus**, and F. Appelbaum, "Cytarabine dose for acute myeloid leukemia (letter)," *New England Journal of Medicine*, 364(22), pages 2167–2168, 2011. PMID: 21631340.
48. **M. Othus**, J. Moon, and K. Margolin, "Melanoma's deadly march to the brain," *Cancer*, 117(8), pages 1560–1563, 2011. PMID: 21472703.
49. J. D. Allen, **M. Othus**, A. Hart, A. P. Mohllajee, Y. Li, and D. Bowen, "Do men make informed decisions about prostate cancer screening? Baseline results from the "Take the Wheel" trial," *Medical Decision Making*, 31(1), pages 108–120, 2011. PMID: PMC4386607.
50. **M. Othus** and Y. Li, "A Gaussian copula model for multivariate survival data," *Statistics in Biosciences*, 2(2), pages 154–179, 2010. PMID: PMC3232005.
51. J. D. Allen, **M. Othus**, A. Hart, L. Tom, Y. Li, D. Berry, and D. Bowen, "A randomized trial of a computer-tailored decision aid to improve prostate cancer screening decisions: Results from the Take the Wheel trial," *Cancer Epidemiology Biomarkers & Prevention*, 19(9), pages 2172–2186, 2010. PMID: PMC4386842.
52. J. D. Allen, **M. Othus**, R. C. Shelton, Y. Li, N. Norman, L. Tom, and M. G. del Carmen, "Parental decision making about the HPV vaccine," *Cancer Epidemiology Biomarkers & Prevention*, 19(9), pages 2187–2198, 2010. PMID: 20826829.
53. H. B. Caglar, **M. Othus**, and A. M. Allen, "Esophagus in-field: A new predictor for esophagitis," *Radiotherapy and Oncology*, 97(1), pages 48–53, 2010. PMID: 20832884.
54. B. C. Medeiros, **M. Othus**, M. Fang, D. Roulston, and F. R. Appelbaum, "Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience," *Blood*, 116(13), pages 2224–2228, 2010. PMID: PMC3709629.
55. M. R. Litzow, **M. Othus**, L. D. Cripe, S. D. Gore, H. M. Lazarus, S. J. Lee, J. M. Bennett, E. M. Paietta, G. W. Dewald, J. M. Rowe, and M. S. Tallman, "Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: A report from the Eastern Cooperative Oncology Group," *British Journal of Haematology*, 148(2), pages 217–225, 2010. PMID: PMC2809127.
56. M. De Jesus, L. Parast, R. C. Shelton, K. Kokkinogenis, **M. Othus**, Y. Li, and J. D. Allen, "Actual vs preferred sources of human papillomavirus information among black, white, and hispanic parents," *Archives of Pediatrics & Adolescent Medicine*, 163(11), pages 1066–1067, 2009. PMID: PMC2914618.
57. **M. Othus**, Y. Li, and R. Tiwari, "A class of semiparametric mixture cure survival models with dependent censoring," *Journal of the American Statistical Association*, 104(487), pages 1241–1250, 2009. PMID: PMC2920213.

58. J. D. Allen, A. P. Mohllajee, R. C. Shelton, **M. Othus**, H. B. Fontenot, and R. Hanna, "Stage of adoption of the human papillomavirus vaccine among college women," *Preventive medicine*, 48(5), pages 420–425, 2009. PMID: 19133288.
59. H. B. Caglar, E. H. Baldini, **M. Othus**, M. S. Rabin, R. Bueno, D. J. Sugarbaker, S. J. Mentzer, P. A. Jänne, B. E. Johnson, and A. M. Allen, "Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery," *Cancer*, 115(18), pages 4156–4166, 2009. PMID: 19551884.
60. H. B. Caglar, R. B. Tishler, **M. Othus**, E. Burke, Y. Li, L. Goguen, L. J. Wirth, R. I. Haddad, C. M. Norris, L. E. Court, D. J. Aninno, M. R. Posner, and A. M. Allen, "Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy," *International Journal of Radiation Oncology* Biology* Physics*, 72(4), pages 1110–1118, 2008. PMID: 19551884.
61. J. Rusby, E. Brachtel, **M. Othus**, J. Michaelson, F. Koerner, and B. Smith, "Development and validation of a model predictive of occult nipple involvement in women undergoing mastectomy," *British Journal of Surgery*, 95(11), pages 1356–1361, 2008. PMCID: PMC3576704.
62. L. J. Wirth, J. F. Krane, Y. Li, **M. Othus**, A. E. Moran, D. M. Dorfman, C. M. Norris, L. Goguen, M. R. Posner, R. I. Haddad, and M. M. Bertagnollu, "A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions," *Cancer Prevention Research*, 1(5), pages 339–348, 2008. PMID: 19138978.